Hurvitz SA, Hu Y, O’Brien N, Finn RS (2013) Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev 39(3):219–229

Article  PubMed  CAS  Google Scholar 

Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A et al (2021) ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 32(12):1475–1495

Article  PubMed  CAS  Google Scholar 

Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH et al (2022) Breast cancer, version 3.2022, NCCN Clinical Practice Guidelines in oncology. J Nat Compr Cancer Netw 20(6):691–722

Article  Google Scholar 

Institut national du cancer (2022) Traitements locorégionaux des cancers du sein infiltrants non métastatiques, Collection Recommandations et référentiels. https://e-cancer.fr. Accessed 12 Dec 2022

Groheux D, Hindié E, Delord M, Giacchetti S, Hamy AS, de Bazelaire C et al (2012) Prognostic impact of 18 FDG-PET-CT findings in clinical stage III and IIB breast cancer. JNCI J Nat Cancer Inst 104(24):1879–1887

Article  PubMed  Google Scholar 

Lebon V, Alberini JL, Pierga JY, Diéras V, Jehanno N, Wartski M (2017) Rate of distant metastases on 18F-FDG PET/CT at initial staging of breast cancer: comparison of women younger and older than 40 years. J Nucl Med 58(2):252–257

Article  PubMed  CAS  Google Scholar 

Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471–1474

Article  PubMed  Google Scholar 

Ferrero-Poüs M, Trassard M, Le Doussal V, Hacène K, Tubiana-Hulin M, Spyratos F (2001) Comparison of enzyme immunoassay and immunohistochemical measurements of estrogen and progesterone receptors in breast cancer patients. Appl Immunohistochem Mol Morphol 9(3):267–275

Article  PubMed  Google Scholar 

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American pathologists Clinical Practice Guideline focused update. J Clin Oncol 36(20):2105–2122

Article  PubMed  CAS  Google Scholar 

Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403–410

Article  PubMed  CAS  Google Scholar 

Han S, Woo S, Kim YJ, Suh CH (2018) Impact of 68 Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol 74(2):179–190

Article  PubMed  CAS  Google Scholar 

Seo MJ, Lee JJ, Kim HO, Chae SY, Park SH, Ryu JS et al (2014) Detection of internal mammary lymph node metastasis with 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stage III breast cancer. Eur J Nucl Med Mol Imaging 41(3):438–445

Article  PubMed  Google Scholar 

Han S, Choi JY (2021) Impact of 18F-FDG PET, PET/CT, and PET/MRI on staging and management as an initial staging modality in breast cancer. Clin Nucl Med 46(4):271–282

Article  PubMed  PubMed Central  Google Scholar 

Cochet A, Dygai-Cochet I, Riedinger JM, Humbert O, Berriolo-Riedinger A, Toubeau M et al (2014) 18F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations. Eur J Nucl Med Mol Imaging 41(3):428–437

Article  PubMed  Google Scholar 

Kong E, Choi J (2021) The new perspective of PET/CT for axillary nodal staging in early breast cancer patients according to ACOSOG Z0011 trial PET/CT axillary staging according to Z0011. Nucl Med Commun 42(12):1369–1374

Article  PubMed  CAS  Google Scholar 

Gil-Rendo A, Zornoza G, García-Velloso MJ, Regueira FM, Beorlegui C, Cervera M (2006) Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg 93(6):707–712

Article  PubMed  CAS  Google Scholar 

Borm KJ, Oechsner M, Düsberg M, Buschner G, Weber W, Combs SE et al (2020) Irradiation of regional lymph node areas in breast cancer—dose evaluation according to the Z0011, AMAROS, EORTC 10981–22023 and MA-20 field design. Radiother Oncol 142:195–201

Article  PubMed  CAS  Google Scholar 

Borm KJ, Voppichler J, Düsberg M, Oechsner M, Vag T, Weber W et al (2019) FDG/PET-CT-based lymph node atlas in breast cancer patients. Int J Radiat Oncol Biol Phys 103(3):574–582

Article  PubMed  Google Scholar 

Krammer J, Schnitzer A, Kaiser CG, Buesing KA, Sperk E, Brade J et al (2015) 18 F-FDG PET/CT for initial staging in breast cancer patients—Is there a relevant impact on treatment planning compared to conventional staging modalities? Eur Radiol 25(8):2460–2469

Article  PubMed  CAS  Google Scholar 

Ulaner GA, Castillo R, Goldman DA, Wills J, Riedl CC, Pinker-Domenig K et al (2016) 18F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer. Eur J Nucl Med Mol Imaging 43(11):1937–1944

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ulaner GA, Castillo R, Wills J, Gönen M, Goldman DA (2017) 18F–FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer. Eur J Nucl Med Mol Imaging 44(9):1420–1427

Article  PubMed  CAS  Google Scholar 

Koolen BB, Valdés Olmos RA, Elkhuizen PHM, Vogel WV, Vrancken Peeters MJTFD, Rodenhuis S et al (2012) Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy. Breast Cancer Res Treat 135(1):231–240

Article  PubMed  Google Scholar 

Sebro R, Aparici CM, Pampaloni MH (2013) Frequency and clinical implications of incidental new primary cancers detected on true whole-body 18F-FDG PET/CT studies. Nucl Med Commun 34(4):333–339

Article  PubMed  Google Scholar